STOCK TITAN

Altimmune Inc - ALT STOCK NEWS

Welcome to our dedicated news page for Altimmune (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Altimmune's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Altimmune's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
conferences clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.63%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.21%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.08%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
conferences clinical trial
Altimmune Inc

Nasdaq:ALT

ALT Rankings

ALT Stock Data

533.13M
70.33M
0.78%
62.24%
25.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Gaithersburg

About ALT

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current